Chaewon Hwang, M.D.

💡Our real-world analysis showed median time to consolidative #immunotherapy of 84 days from CRT start in Stage III #NSCLC (2018-2021). Uninsured, Medicaid, and tx at non-academic center associated w/ longer time to intiation #ASCOQLTY26 @bidmc-cancercenter.bsky.social @ascocancer.bsky.social

💡Compelling study on feasibility of consolidative #durvalumab ≤14days after completion of definitive CRT for #NSCLC without added immune-related toxicity. Interesting contrast to TORG1937 (DATE Study) from Japan. Further food for thought for time to tx intiation #ASCOQLTY26 @ascocancer.bsky.social

#ASTRO26 is officially in session, in Boston! Excited to learn about new advancements, updates in #radonc and for connection & collaboration

#ASTRO26 is upon us! Proud to share our residents' research @bidmc-cancercenter.bsky.social and @TuftsMedicalCtr ! @bidmcreseach.bsky.social

Upcoming Medicaid work requirements starting in 2027 could impact coverage and care delivery for patients with cancer. We break down what these policy changes mean and how we are working to protect patient access to care. Learn more: https://bit.ly/4rcyCA4 #ASCOAdvocacy

Now live on #ASCOConnection! Thank you @ascocancer.bsky.social and @ASCOTECAG for planning this session during #ASCO26 Beyond the Clinic: Building Leadership Skills in Training and Early Career | ASCO Connection connection.asco.org/do/beyond-cl... @bidmc-cancercenter.bsky.social

Deeply honored to receive the #GRASPAdvocateChoiceAward, for our work presented at #ASCO26, www.asco.org/abstracts-pr.... Grateful for my collaborators, especially Jason Jincong Freeman, PhD, and mentor Kathryn Huber, MD PhD. I am excited to share this work with patient advocates 6/11/26!

Incredible finding for treatment of previously treated metastatic pancreatic cancer using targeted therapy. Exciting to see more and more targeted agents emerge that we can use to help treat patients #ASCO26

#RealWorldData on OS differences for px with Stage III #NSCLC s/p #ChemoRT, eligible for #immunotherapy 2018-2020. Treatment facility & insurance = independent predictors of OS. ~54% received IO. IO receipt was associated with 47% mortality risk reduction. #ASCO26 @bidmc-cancercenter.bsky.social

Excited to share our #RealWorldData and evidence on socioeconomic and clinical factors associated with OS in patients with Stage III #NSCLC following #chemoRT in the post-PACIFIC era! Stop by, 9am-12pm, 5/30! #ASCO2026 #LungCancer @ascocancer.bsky.social @bidmc-cancercenter.bsky.social @TuftsMedCtr

Thrilled to be back at @ascocancer.bsky.social annual meeting for #ASCO2026 ! Honored to be a part of this inspiring global oncology community with common goal of conquering cancer

We are thrilled to welcome Rita & Danny to our Residency Program @TuftsMCRadOnc, allied with @BIDMC and @UMass!🎉 #Match2026 #RadOnc #ResidencyMatch

FANSS study: low-dose CT screening feasible, valuable for lung cancer screening for Asian non-smoking women Supports expansion of guidelines to include high-risk populations Presenter: @elaineshummd.bsky.social Discussant: David R. Baldwin, MD ascopost.com/news/october...

Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens - Fumiko Ladd Chino @fumikochino.bsky.social @chaewonhwangmd.bsky.social @jbudhu.bsky.social @bthomphd.bsky.social oncodaily.com/voices/fumik... #OncoDaily #Oncology #Cancer #Health #Medicine #MedOnc #MedNews

#ASTRO25 ! Thank you for the opportunity to present our work on #financialtoxicity in patients undergoing radiation treatment, specifically on baseline FT and cost-coping mechanisms. Stay tuned for #ASCOQLTY25 for subanalysis on our prostate cancer patient cohort! #radonc

Abstract titles for #ASCOQLTY25 are now live! Get a first look at the solution-oriented cancer research that will be presented at the symposium: asco.org/qcs-abstracts If you haven’t yet confirmed your attendance, registration is still open: brnw.ch/21wVpzR

More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8 #ASCODailyNews #GICSM

Day 3 of #ASCO25 ! Honored to be presenting on how social determinants of health affect immunotherapy use in Stage III NSCLC patients after definitive chemoradiation @ascocancer.bsky.social @bidmcreseach.bsky.social @bidmc-cancercenter.bsky.social #TuftsMedicalCenter

Day 2 of #ASCO25! Exciting new frontiers in harnessing power of AI to better cancer care! As Dr. Robin Zon, President of @ascocancer.bsky.social, & Ms. Ruth Porat, President & CIO of Google and Alphabet, mentioned, AI is augmenting human capabilities, and it's about using it as an agent for change

@cliffordhudis.bsky.social at #ASCO25: ~40% cut to NCI budget in Admin's '26 proposal. We are in a tragic paradox: remarkable science & historic cuts to resources needed to turn these opps into hope for millions of pts. Our advocacy, is more important than ever ➡️ brnw.ch/21wT3U4

Thrilled to be at #ASCO25 ! Excited to witness and be a part of the forefront of cancer research! And honored to present research @ascocancer.bsky.social

The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH

Incredible findings of Phase II study where px with stage I, II, or III dMMR solid tumors that were amenable to curative-intent surgery were treated with neoaduvant dostarlimab for 6 months: ➡️ recurrence-free survival at 2 years was 92% #AACR25 #Oncology #research www.nejm.org/doi/full/10....

📣 Phase III KEYNOTE-689 trial: Addition of perioperative Pembrolizumab to standard of care tx for locally advanced HNSCC significantly improved event free survival and major pathologic response. Presented @ #AACR 2025 meeting: www.aacr.org/about-the-aa... #Oncology #research #radonc

Helpful guide to responding to reviewers, when submitting research to journals: www.sciencedirect.com/science/arti... #meded #oncology #research #radonc

Excited to be presenting our research #ASCO meeting this year! Can't wait to share our findings on patterns of immunotherapy use in different groups of stage 3 NSCLC patients who were treated definitively with chemoRT: meetings.asco.org/abstracts-pr... @bidmcreseach.bsky.social #TuftsMedicine

📣 Big shoutout to our faculty at #TuftsMedicine & @bidmc-cancercenter.bsky.social radiation oncology residency, Dr. Jang and Dr. Huber, for being speaker and moderator at this year's @astro-org.bsky.social Annual RefresherCourse! Thank you for all that you do for us and for the #radonc community!

"Deintensification of chemoradiation treatments for HPV-associated oropharyngeal cancers is of very high interest to patients and researchers, but our study makes clear that these approaches should remain experimental.” — SUE YOM, MD, PhD, FASTRO. ascopost.com/news/april-2... @ascopost.bsky.social

We had a record number of abstracts submitted for #ACRO2025! 👏 Impressive work by all our residents who presented at #ACROinVegas! See all the photos here: www.facebook.com/media/set?va...